These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
439 related articles for article (PubMed ID: 19431143)
1. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143 [TBL] [Abstract][Full Text] [Related]
2. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model. Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879 [TBL] [Abstract][Full Text] [Related]
3. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738 [TBL] [Abstract][Full Text] [Related]
4. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Saidi A; Javerzat S; Bellahcène A; De Vos J; Bello L; Castronovo V; Deprez M; Loiseau H; Bikfalvi A; Hagedorn M Int J Cancer; 2008 May; 122(10):2187-98. PubMed ID: 18092325 [TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor microRNA‑613 inhibits glioma cell proliferation, invasion and angiogenesis by targeting vascular endothelial growth factor A. Yu X; Wang W Mol Med Rep; 2017 Nov; 16(5):6729-6735. PubMed ID: 28901424 [TBL] [Abstract][Full Text] [Related]
6. Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication. Hoshino Y; Hayashida T; Hirata A; Takahashi H; Chiba N; Ohmura M; Wakui M; Jinno H; Hasegawa H; Maheswaran S; Suematsu M; Kitagawa Y Mol Cancer; 2014 May; 13():102. PubMed ID: 24885802 [TBL] [Abstract][Full Text] [Related]
7. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228 [TBL] [Abstract][Full Text] [Related]
8. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model. Bhuvaneswari R; Yuen GY; Chee SK; Olivo M Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493 [TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma. Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979 [TBL] [Abstract][Full Text] [Related]
11. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Saleh M; Stacker SA; Wilks AF Cancer Res; 1996 Jan; 56(2):393-401. PubMed ID: 8542597 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820 [TBL] [Abstract][Full Text] [Related]
14. Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas. Li Y; Fu SY; Wang LH; Wang FY; Wang NN; Cao Q; Wang YT; Yang JY; Wu CF Cancer Lett; 2015 Dec; 369(1):86-96. PubMed ID: 26254539 [TBL] [Abstract][Full Text] [Related]
15. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704 [TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin. Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS Cancer Biol Ther; 2014 Apr; 15(4):398-408. PubMed ID: 24424202 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592 [TBL] [Abstract][Full Text] [Related]
18. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Lucio-Eterovic AK; Piao Y; de Groot JF Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589 [TBL] [Abstract][Full Text] [Related]
19. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo. Atzori MG; Tentori L; Ruffini F; Ceci C; Bonanno E; Scimeca M; Lacal PM; Graziani G J Pharmacol Exp Ther; 2018 Jan; 364(1):77-86. PubMed ID: 29025978 [TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]